Ellie Rashidghamat

Phase I/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa

Ellie Rashidghamat, Tendai Kadiyirire, Salma Ayis et al. · Journal of the American Academy of Dermatology · 2019 · 109 citations · Full text

Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa

Su M. Lwin, Farhatullah Syed, Wei‐Li Di et al. · JCI Insight · 2019 · 88 citations · Full text

Early Efficacy Outcomes, Immunology, Pathology +19

Transcriptomic profiling of recessive dystrophic epidermolysis bullosa wounded skin highlights drug repurposing opportunities to improve wound healing

Alexandros Onoufriadis, Laura E. Proudfoot, Chrysanthi Ainali et al. · Experimental Dermatology · 2021 · 23 citations

Transcriptomic Profiling, Immunology, Pathology +20

Follicular T-Helper Cells in Marginal Zone Lymphoma: Evidence of an Organoid Immune Response

Alistair Robson, Farrah Bakr, Ellie Rashidghamat et al. · American Journal of Dermatopathology · 2021 · 21 citations

T-regulatory Cell, Immune Regulation, Immunology +17